AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04488419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
Trial: NCT01432353
Drug: DFRF4539A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple ascending doses
Trial: NCT01971593
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00324194
Drug: MGCD0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGCD0103 oral dose given 2 times per week.
Trial: NCT01696214
Drug: Theophylline 400 mg
RxNorm normalized name: theophylline 400 MG
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be assigned to theophylline once a day for 24 weeks
Trial: NCT02957123
Drug: Intranasal auto-M2-BFs
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
Trial: NCT00449007
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 months
Trial: NCT04333654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT03511066
Drug: CT-P27 90 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza A treatment drug.
Trial: NCT03511066
Drug: CT-P27 45 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza A treatment drug.
Trial: NCT03511066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo.
Trial: NCT01089543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
Trial: NCT03693508
Drug: Genvoya®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
Trial: NCT01898091
Drug: Neem Mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
Trial: NCT01898091
Drug: Placebo Mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
Trial: NCT02575183
Drug: Varinecline (Chantix)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
Trial: NCT02575183
Drug: Placebo (for Varenicline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
Trial: NCT01725308
Drug: FK949E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken by mouth (orally).
Trial: NCT01725308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken by mouth (orally).
Trial: NCT00598975
Drug: NKTR-102 125 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-102 125 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled.
Trial: NCT04560114
Drug: Essential oils
RxNorm normalized name: essential oils
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be invited to inhale the essential oils via the stick:~* 4 times a day before each meal and snack.~* if necessary when nausea appears, as many times as he deems necessary.
Trial: NCT03593447
Drug: non-cirrhotic subjects. low TG-2349+ low DAG181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: TG-2349 200 mg + DAG181 100 mg
Trial: NCT03593447
Drug: non-cirrhotic subjects. high TG-2349+ high DAG181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4: TG-2349 400 mg + DAG181 200 mg
Trial: NCT03593447
Drug: cirrhotic subjects. high TG-2349+ high DAG181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group6: TG-2349 400 mg + DAG181 200 mg
Trial: NCT02552654
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10mg
Trial: NCT02552654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01812746
Drug: BIND-014
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02484729
Drug: AZD9977, oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
Trial: NCT02484729
Drug: Placebo, oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02484729
Drug: AZD9977, oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9977, single dose of oral solution in Part B as reference
Trial: NCT02218268
Drug: Pre-meal bolus
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
Trial: NCT02218268
Drug: No meal bolus
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long Acting insulin as scheduled per usual routine (given once daily)
Trial: NCT03724097
Drug: target drug with the score above 0,1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: target drug with the score above 0,1
Trial: NCT03724097
Drug: target drug with the score equal or below 0,1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: target drug with the score equal or below 0,1
Trial: NCT03724097
Drug: non-target drug
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-target drug
Trial: NCT03724097
Drug: palliative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palliative care
Trial: NCT00689052
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04227522
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
Trial: NCT01740427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Trial: NCT02614066
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT03542357
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Trial: NCT00541489
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg, bid
Trial: NCT00541489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bid
Trial: NCT00531817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
Trial: NCT00531817
Drug: Permitted DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
Trial: NCT03624036
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT01514175
Drug: IV Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
Trial: NCT01514175
Drug: IV Ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
Trial: NCT01691313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT01666613
Drug: AZD8683
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
Trial: NCT01666613
Drug: AZD8683
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution to be administered orally Total dose of 950 µg AZD8683
Trial: NCT01666613
Drug: AZD8683
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
Trial: NCT01666613
Drug: AZD8683
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
Trial: NCT01390584
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01390584
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: May be given orally, IV push, or by IV infusion
Trial: NCT03782103
Drug: ZuraPrep Clear Solution
RxNorm normalized name: DuraPrep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT03782103
Drug: ZuraPrep Vehicle
RxNorm normalized name: DuraPrep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically.
Trial: NCT00220714
Drug: atypical antipsychotics:oral vs. long-acting route
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04428593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
Trial: NCT00562861
Drug: placebo + mood stabilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
Trial: NCT02473263
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
Trial: NCT02473263
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
Trial: NCT02405065
Drug: HM95573
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
Trial: NCT02687165
Drug: Milnacipran and D-cycloserine
RxNorm normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milnacipran augmented by D-cycloserine
Trial: NCT04007874
Drug: Ethinylestradiol/levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
Trial: NCT00667589
Drug: bland emollient cream (Udderly smooth® Udder Cream)
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bland emollient cream applied twice per day to affected areas
Trial: NCT00002836
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
Trial: NCT00553475
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
Trial: NCT00484900
Drug: Co-Arinate FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03061331
Drug: LUM/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUM 400 mg/IVA 250 mg every 12 hours (q12h)
Trial: NCT03061331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Active Drug
Trial: NCT02567032
Drug: Saline Nasal Spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Trial: NCT04177342
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
Trial: NCT02605694
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~* Cyclophosphamide (750 mg/m2)~* Doxorubicin hydrochloride (50 mg/m2)~* Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~* Rituximab (375 mg/m2)
Trial: NCT02074137
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT01955837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Trial: NCT02548364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control group
Trial: NCT02440399
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02440399
Drug: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01438944
Drug: Nicabate 21mg transdermal NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
Trial: NCT00470067
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01301001
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 capsules am and 3 capsules pm
Trial: NCT02635789
Drug: NPC-12G gel
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-12G gel is administered topically twice a day for 12 weeks
Trial: NCT02635789
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-12G gel placebo is administered topically twice a day for 12 weeks
Trial: NCT03043820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets identical in form and color to intervention.
Trial: NCT01279187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ug per day, self administered injection, for 7 weeks
Trial: NCT03954938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
Trial: NCT00781664
Drug: AN2718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2718 Cream SF, 0.3%, Daily for up to 21 days
Trial: NCT00781664
Drug: AN2718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2718 Cream SF, 1%, Daily for up to 21 days
Trial: NCT00781664
Drug: AN2718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2718 Gel, 1.5%, Daily for up to 21 days
Trial: NCT00781664
Drug: AN2718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2718 Gel, 2.5%, Daily for up to 21 days
Trial: NCT00781664
Drug: AN2718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2718 Gel, 5%, Daily for up to 21 days
Trial: NCT00781664
Drug: AN2718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2718 Gel, 7.5%, Daily for up to 21 days
Trial: NCT01862965
Drug: PredEver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firstline treatment with prednisone and Everolimus
Trial: NCT04405843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
Trial: NCT00003151
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003151
Drug: tetracycline hydrochloride
RxNorm normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01286935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01096186
Drug: IPX066 95 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23.75 - 95 mg CD-LD capsules
Trial: NCT01096186
Drug: IPX066 145 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36.25 - 145 mg CD-LD capsules
Trial: NCT01096186
Drug: IPX066 195 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48.75 - 195 mg CD-LD capsules
Trial: NCT01096186
Drug: IPX066 245 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 61.25 - 245 mg CD-LD capsules
Trial: NCT01367756
Drug: RO4995819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses, Days 10-16
Trial: NCT01367756
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses, Days 10-16
Trial: NCT00143520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01104337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment consisted of two matching placebo tablets three times a day.
Trial: NCT00790660
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00790660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00629642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02656342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predicted to have no enhancing effect
Trial: NCT00512083
Drug: AS1411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
Trial: NCT02046200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT03156452
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg tablets for oral administration
Trial: NCT00005922
Drug: Dose control for Arm B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
Trial: NCT03559400
Drug: local gentamicin injection
RxNorm normalized name: gentamicin Injection
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
Trial: NCT02417337
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02417337
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02417337
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03400943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo was administered to group B1 and B2.
Trial: NCT01623284
Drug: F-18 FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
Trial: NCT02622594
Drug: Aminolevulinic Acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no